Stockscreener 앱 받기
8.085
1.07%
-0.065
전일 마감가:
$8.15
열려 있는:
$8.25
하루 거래량:
9,873
Relative Volume:
0.05
시가총액:
$443.97M
수익:
$79.55M
순이익/손실:
$-37.25M
주가수익비율:
-11.46
EPS:
-0.7054
순현금흐름:
$-25.40M
1주 성능:
-0.95%
1개월 성능:
+64.22%
6개월 성능:
+49.31%
1년 성능:
+95.70%
1일 변동 폭
$8.05
$8.25
1주일 범위
$7.89
$8.85
52주 변동 폭
$3.19
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
명칭
Sight Sciences Inc
전화
(415) 889-0550
주소
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
8.0592 | 466.60M | 79.55M | -37.25M | -25.40M | -0.7054 |
ABT
Abbott Laboratories
|
114.56 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.92 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.21 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.62 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.54 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-08-08 | 업그레이드 | Lake Street | Hold → Buy |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-11-04 | 다운그레이드 | Lake Street | Buy → Hold |
| 2024-08-21 | 개시 | Lake Street | Buy |
| 2023-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-06 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-04 | 개시 | Needham | Hold |
| 2022-07-26 | 개시 | Stifel | Hold |
| 2022-02-03 | 개시 | William Blair | Outperform |
| 2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Sight Sciences Inc 주식(SGHT)의 최신 뉴스
FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System - VisionMonday.com
Sight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye Disease - Quiver Quantitative
GSA Capital Partners LLP Makes New Investment in Sight Sciences, Inc. $SGHT - MarketBeat
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Sight Sciences Earnings Call Shows Growth And Discipline - TipRanks
Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares - Stock Titan
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - Kalkine
Sight Sciences (SGHT) Pulls Back to $8.14: Range-Bound Move Tests Key Support ZoneVol Target Rebalance - Vinanet
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
SGHT Q2 2026 Earnings: Narrowed Loss Beats Estimates, Shares Jump 6.49%Earnings Turnaround - Vinanet
SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale - Stock Titan
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com - Investing.com Australia
Sight Sciences Names Kashif Rashid as New Chief Legal Officer Amid Leadership Change - Kalkine Media
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy Hayden - Bitget
Sight Sciences Appoints New Chief Legal Officer Rashid - tipranks.com
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down - Investing.com Nigeria
Form 8K Sight Sciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Revolution Medicines (RVMD) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating - marketscreener.com
Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside - TradingView
Sight Sciences Q2 Earnings Call Highlights - MarketBeat
Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance - VisionMonday.com
Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance - Yahoo Finance
Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall - Investing.com Nigeria
Sight Sciences, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Sight Sciences : Reports Second Quarter 2026 Financial Results - marketscreener.com
Sight Sciences wins FDA clearance for Omni Surgical System - MassDevice
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com - Investing.com South Africa
Sight Sciences Q2 revenue rises 20%, beats estimates - TradingView
Aetna covers Sight Sciences glaucoma devices for commercial plans - Investing.com
Sight Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Sight Sciences, Inc. Q2 2026: Revenue $23.39M, EPS $(0.08) — 10-Q Summary - TradingView
Sight Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Sight Sciences (NASDAQ: SGHT) lifts 2026 outlook after 20% Q2 growth - Stock Titan
Sight Sciences Reports Second Quarter 2026 Financial Results - The Manila Times
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems - The Manila Times
BRIEF-Sight Sciences Q2 Revenue USD 23.4 Million Vs. IBES Estimate USD 21.7 Million - TradingView
Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms - Bitget
Sight Sciences Inc (SGHT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.75%
자본화:
|
볼륨(24시간):